Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CureVac (CVAC) Receivables (2019 - 2025)

Historic Receivables for CureVac (CVAC) over the last 7 years, with Q3 2025 value amounting to $22.9 million.

  • CureVac's Receivables rose 26195.6% to $22.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.9 million, marking a year-over-year increase of 26195.6%. This contributed to the annual value of $18.0 million for FY2024, which is 209.53% down from last year.
  • CureVac's Receivables amounted to $22.9 million in Q3 2025, which was up 26195.6% from $462971.5 recorded in Q2 2025.
  • Over the past 5 years, CureVac's Receivables peaked at $25.9 million during Q2 2024, and registered a low of $10103.3 during Q1 2022.
  • Its 5-year average for Receivables is $10.4 million, with a median of $9.0 million in 2022.
  • In the last 5 years, CureVac's Receivables plummeted by 9986.93% in 2023 and then soared by 13922889.92% in 2024.
  • Over the past 5 years, CureVac's Receivables (Quarter) stood at $24.3 million in 2021, then plummeted by 62.81% to $9.0 million in 2022, then soared by 103.67% to $18.4 million in 2023, then dropped by 2.1% to $18.0 million in 2024, then rose by 27.32% to $22.9 million in 2025.
  • Its Receivables stands at $22.9 million for Q3 2025, versus $462971.5 for Q2 2025 and $4.2 million for Q1 2025.